Ramasethu Jayashree
Division of Neonatology, Georgetown University Hospital, 3800 Reservoir Road NW, Suite M3400, Washington, DC 20007, USA.
Curr Hematol Rep. 2004 Mar;3(2):134-42.
Thrombocytopenia is the most common hemostatic abnormality in sick newborn infants. Although many conditions may be associated with neonatal thrombocytopenia, low platelet counts in the first few days of life are often caused by fetomaternal problems, whereas thrombocytopenia developing after the third day is usually secondary to sepsis or necrotizing enterocolitis. Despite the frequency of thrombocytopenia in sick neonates, the underlying kinetic mechanisms are not always clear. The commonly accepted theories of decreased platelet production or increased consumption are being scrutinized in the light of new evidence. Thrombopoietin and interleukin-11 are being investigated to unravel the complex pathophysiology of thrombocytopenia in neonates and they are also being explored as potential therapeutic agents. Guidelines for platelet transfusions continue to be variable and controversial.
血小板减少症是患病新生儿中最常见的止血异常。尽管许多情况可能与新生儿血小板减少症有关,但出生后最初几天血小板计数低通常是由母婴问题引起的,而出生第三天后出现的血小板减少症通常继发于败血症或坏死性小肠结肠炎。尽管患病新生儿中血小板减少症很常见,但其潜在的动力学机制并不总是清楚。鉴于新的证据,关于血小板生成减少或消耗增加的普遍接受的理论正在受到审视。正在研究血小板生成素和白细胞介素-11,以阐明新生儿血小板减少症复杂的病理生理学,并且它们也正在作为潜在的治疗药物进行探索。血小板输注指南仍然存在差异且存在争议。